Navigation Links
ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

MOUNTAIN VIEW, Calif., Jan. 6, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at J.P. Morgan's 29th Annual Healthcare Conference on Wednesday, January 12, 2011, at 10:00 a.m. Pacific at the Westin St. Francis Hotel in San Francisco, CA.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. Phase III clinical trials of Traficet-EN are expected to initiate in the first quarter 2011. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
2. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
3. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
4. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
8. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
9. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
10. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
11. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... San Rafael, CA (PRWEB) , ... May 05, 2016 , ... ... Coach of the Year, Derek Pittman, along with his university coaching staff. Together they ... and girls, with separate sessions run for youth players ages 5-13, and high school ...
(Date:5/5/2016)... ... 05, 2016 , ... Chronic stress can have a silent, yet dangerous, impact ... immune system and increase inflammation, both of which raise the risk of heart attack ... disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other ...
(Date:5/5/2016)... ... , ... With May flowers, summer is just around the corner. Summer means a lot of ... and the ability to play all day and night. Parents often lament the coming of ... tykes themselves. Summer also means trips to the beach, backyard cookouts, fireworks on the Fourth ...
(Date:5/5/2016)... ... May 05, 2016 , ... MAP Health ... announced today that Enlightened Solutions has joined the Premier Outcomes-Driven Provider Network. By ... continuum for their patients being treated for substance use. , Enlightened Solutions was ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... In the ... easy to forget the most important arrangement — planning a safe way of getting ... and popular tequila drinks. Unfortunately, these celebrations often lead to drunk drivers on the ...
Breaking Medicine News(10 mins):